Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.57.
A number of brokerages have recently commented on MRSN. Citigroup downgraded Mersana Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 27th. Guggenheim cut Mersana Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 27th. Truist Financial reaffirmed a “hold” rating on shares of Mersana Therapeutics in a report on Thursday, July 27th. Robert W. Baird cut Mersana Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Friday, July 28th. Finally, Wedbush reissued a “neutral” rating and set a $2.00 target price on shares of Mersana Therapeutics in a research note on Tuesday, August 8th.
Hedge Funds Weigh In On Mersana Therapeutics
Mersana Therapeutics Trading Down 3.7 %
Shares of NASDAQ:MRSN opened at $1.16 on Friday. The business’s 50-day moving average is $1.31 and its 200 day moving average is $3.49. Mersana Therapeutics has a 1 year low of $0.80 and a 1 year high of $9.62. The firm has a market capitalization of $139.79 million, a P/E ratio of -0.57 and a beta of 1.38. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.97 and a quick ratio of 3.97.
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last announced its earnings results on Tuesday, August 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.03). The business had revenue of $10.70 million for the quarter, compared to analyst estimates of $12.93 million. Mersana Therapeutics had a negative net margin of 555.84% and a negative return on equity of 255.91%. The firm’s quarterly revenue was up 148.8% on a year-over-year basis. On average, research analysts predict that Mersana Therapeutics will post -1.5 earnings per share for the current fiscal year.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates.
- Five stocks we like better than Mersana Therapeutics
- The How and Why of Investing in Gold Stocks
- Is domestic travel back on track? Check out these companies
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 10/23 – 10/27
- How to Calculate Return on Investment (ROI)
- Can casino stocks win big if economy slows?
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.